Epigral Limited has informed the Exchange regarding Outcome of Board Meeting held on May 05, 2025.
EPIGRAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Epigral Limited reported strong FY25 results with standalone revenue from operations rising ~32% to ₹2,550.13 Cr (vs ₹1,929.19 Cr in FY24). Profit after tax surged ~82% to ₹356.70 Cr (vs ₹195.79 Cr), translating to EPS of ₹84.45 (vs ₹47.12). Q4 FY25 revenue stood at ₹627.63 Cr with PAT of ₹86.62 Cr. The Board declared a final dividend of ₹3.50 (35%) per share of face value ₹10. During the year, the company raised ₹333.05 Cr via a QIP at ₹2,093.13 per share, using ₹250 Cr to repay debt, ₹30 Cr for capex, and the rest for general corporate purposes. The statutory auditor SRBC & Co LLP issued an unmodified opinion. EBITDA margin expanded meaningfully as finance costs fell sharply (₹53.27 Cr vs ₹73.49 Cr) on the back of debt reduction.
Strong topline and bottomline growth, falling finance costs from QIP-led deleveraging, and a 35% final dividend should support positive sentiment. The 2-for-15 bonus-like jump in EPS underscores operational leverage, though Q4 sequential decline (PAT down from ₹103.54 Cr in Q3) may temper near-term enthusiasm.